In today’s briefing:
- The Stocks to Own in Asia – Vol. 38
- Indian Generic Pharmaceutical Companies: The US Business Is Recovering Slowly
- The Stocks to Own in ASEAN – Vol. 40
The Stocks to Own in Asia – Vol. 38
- We highlight 14 stocks in Asia that look interesting to us based on our FVMR methodology
- Six stock remains, and eight stocks added to our portfolio
- Since its inception, it has generated a before-fee total return of 93% versus the MSCI Asia ex Japan of 55%
Indian Generic Pharmaceutical Companies: The US Business Is Recovering Slowly
- Most of the large Indian pharmaceutical companies have reported double-digit revenue growth in their respective U.S. business in Q1FY23. New launches are mostly offsetting the impact of price erosion.
- Although the companies are still facing price erosion in the U.S. market, the pace has slowed down. Price erosion seems to be near its bottom.
- Dr. Reddy’s Laboratories (DRRD IN) and Zydus Lifesciences Ltd (ZYDUSLIF IN) remain our top picks. Aided by new launches both the companies are seeing sustainable recovery in U.S. business.
The Stocks to Own in ASEAN – Vol. 40
- We highlight 14 stocks in ASEAN that look interesting to us based on our FVMR Methodology
- Portfolio changes: Six stocks remain, and eight stocks added to the portfolio
- Since its inception, the portfolio has generated a before-fee total return of 184% versus MSCI ASEAN’s 24%
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
